Skip to main content


Freshfields advises Hasten Biopharmaceuticals on acquisition of Celltrion Healthcare product portfolios

Global law firm Freshfields Bruckhaus Deringer (‘Freshfields’) has advised Hasten Biopharmaceuticals on its acquisition of 14 product portfolios from Korean biopharmaceutical company Celltrion Healthcare.

Hasten Biopharmaceuticals is a leading specialty pharmaceutical company based in China and a portfolio company of CBC Group, a healthcare-dedicated asset management firm headquartered in Singapore.

The Freshfields team advising on the transaction was led by partner Alan Wang and counsel Ya Ma, supported by associates Sunny Min and Yichen Xing. Teams in Europe provided support on IP matters and various commercial agreements, comprised by partners David Brooks and Philipp Dohnke, counsel Philipp Lehman and John Scurr, senior associate Ben Cohen and associate Babak Hakimian.